Key Points Actuate Therapeutics reported preclinical data showing that elraglusib enhanced the activity of two investigational RAS-targeted therapies in pancreatic cancer models. The studies tested…
September 09, 2026
Key Points Adlai Nortye dosed the first patient in Australia in a global Phase 1 trial of AN4035. The U.S. FDA cleared the company’s IND…
September 04, 2026
AbbVie’s Etentamig Shows Strong Results in Phase 3 Blood Cancer Study
Key Points AbbVie’s experimental drug etentamig helped more patients with hard-to-treat multiple myeloma respond to treatment than standard therapies. The drug cut the risk of…
September 01, 2026
bioAffinity Expands CyPath Lung Toward Monitoring Lung Cancer Survivors
Key Points bioAffinity Technologies is advancing CyPath® Lung for use in monitoring lung cancer survivors after treatment. The noninvasive sputum-based test is designed to provide…
August 26, 2026
FDA Approves Revolution Medicines’ Rasonque for Metastatic Pancreatic Cancer, Months Ahead of Schedule
Key Points The FDA approved daraxonrasib under the brand name Rasonque for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic…
Key Points Verastem Oncology reported $25.1 million in Q2 2026 net product revenue from AVMAPKI FAKZYNJA CO-PACK, up 34% sequentially from $18.7 million in Q1….
Ahead of Nuvation Bio’s (NYSE: NUVB) second-quarter results, investors were looking for evidence that the company’s strong first quarter represented the beginning of a sustainable…
Key Points Citius Oncology, Inc. reports accelerating commercial momentum for LYMPHIR, its FDA‑approved treatment for cutaneous T‑cell lymphoma (CTCL). New U.S. institutions ordering LYMPHIR rose…
Key Points BriaCell Therapeutics Corp. received FDA clearance to begin a clinical study of Bria-PROS in prostate cancer. The company is developing Bria-PROS as a…
Corbus Pharmaceuticals received FDA clearance to start its TEMPO‑1 registrational trial. Registrational studies are designed to provide the pivotal data needed to support a future…
bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing…
July 17, 2026
Illuccix Japan Study Hits Full Enrollment as Telix Moves Closer to Prostate Cancer Imaging Approval
Telix Pharmaceuticals (NASDAQ: TLX) has hit a key clinical milestone, finishing patient enrollment in its Phase 3 Illuccix Japan study of TLX591‑Px for prostate cancer…